Dr. Michael Rimlawi Announces Scholarship for Aspiring Physicians
DALLAS, April 01, 2025 (GLOBE NEWSWIRE) -- Spine surgeon Dr. Michael Rimlawi is proud to announce the launch of the Dr. Michael Rimlawi Scholarship for Future Doctors, a prestigious award dedicated to supporting undergraduate and graduate students pursuing a career in medicine. This scholarship, awarded through a competitive essay contest, reflects Dr. Rimlawi's deep commitment to education, innovation, and patient-centered care.
The scholarship is open to students enrolled at accredited institutions who are passionate about becoming doctors. Applicants must submit an original essay responding to the prompt:
What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?
Dr. Rimlawi's own journey into medicine was shaped by a personal experience. After suffering a back injury in college and struggling to find lasting relief through various treatments including chiropractic care, physical therapy, and traditional medicine, he was inspired to make a difference in spinal healthcare. He went on to invent and patent several minimally invasive spine surgery techniques, significantly improving outcomes. His inventions had the benefit of reducing post operative pain, small incisions, minimizing scar tissue, lower infection rates, minimal blood loss, and a quicker recovery time when compared to traditional spine surgery.
As part of their essays, applicants are encouraged to share personal experiences whether their own or those of friends or family that have fueled their passion for improving the healthcare system. Submissions will be evaluated on originality, clarity, and alignment with Dr. Rimlawi's values of medical innovation, excellence, and a drive to disrupt and improve healthcare.
Dr. Rimlawi's dedication to philanthropy extends beyond scholarships. He has long been involved in charitable efforts, from supporting veterans with complex spine injuries to raising funds for pediatric cancer research and providing life-changing medical care through mission trips to underserved countries.
Key Scholarship Details:
. Eligibility: Open to undergraduate and graduate students pursuing a career in medicine
. Application Process: Submit an essay (500-750 words) along with personal and academic r. Deadline: December 15, 2025
. Deadline: December 15, 2025.
. Winner Announcement: January 15, 2026
Dr. Michael Rimlawi is a recognized leader in minimally invasive spine surgery. He was the first U.S. surgeon to perform the Globus Minimally Invasive XLIF procedure and has pioneered revolutionary micro-endoscopic spine surgery. He is patented three medical devices for spine surgery. He was one of the pioneers of being able to perform complex lumbar/cervical surgeries and artificial disc replacements in an outpatient setting due to the minimal blood loss and recovery needed for his Minimally Invasive Spine surgeries. Beyond his contributions to medicine, he is passionate about mentoring future doctors, which led him to establish this scholarship.
Becoming a doctor requires immense dedication, time, and financial resources. My hope is that this scholarship eases the burden for talented students who share my commitment to improving healthcare and making a meaningful impact in patient's lives, said Dr. Michael Rimlawi.
Students interested in applying should submit their essays and required details via email to apply@drmichaelrimlawischolarship.com.
More than just financial aid, this scholarship embodies Dr. Rimlawi's belief in the power of education and innovation to shape the future of medicine. Aspiring physicians are encouraged to seize this opportunity to showcase their passion and dedication to healthcare. Award Amount: $1,000 per winner (at least one recipient, with potential for more).
For more information on the scholarship and application guidelines, visit drmichaelrimlawischolarship.com.
About Dr. Michael Rimlawi
Dr. Michael Rimlawi is a board-certified, fellowship, trained spine surgeon and a pioneer in minimally invasive surgical techniques. He has received numerous accolades, including the Healthcare Heroes award, Top 10 surgeons award, and numerous patient choice awards. He remains dedicated to advancing medical innovation while mentoring future healthcare leaders.
Contact Information:
Spokesperson: Dr. Michael RimlawiOrganization: Dr. Michael Rimlawi ScholarshipWebsite: drmichaelrimlawischolarship.comEmail: apply@drmichaelrimlawischolarship.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c13c96e4-f29c-477f-ba66-e9f793201505Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dr. Ritesh Kalra Scholarship to Support Aspiring Medical Professionals
Dr. Ritesh Kalra Scholarship SECAUCUS, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Dr. Ritesh Kalra Scholarship for Medical Students is now accepting applications for its 2026 award cycle, offering a $1,000 prize to a deserving undergraduate student on the path to becoming a doctor. Established by acclaimed physician Dr. Ritesh Kalra, this initiative seeks to encourage academic excellence, foster a spirit of compassion in medicine, and provide financial assistance to future healthcare leaders. The scholarship will be awarded through an engaging essay contest, providing applicants with an opportunity to share their vision for the future of medicine. Students are invited to reflect on the balance between technological advancements in healthcare and the human connection that remains at the heart of patient care. The award is open to undergraduate students in accredited institutions who are committed to pursuing a medical career. 'This scholarship represents more than financial assistance—it's a way to inspire the next generation of physicians to uphold both innovation and empathy in their work,' said Dr. Kalra. 'Medicine is not only a science; it's a calling that requires skill, dedication, and a genuine desire to help others.' About Dr. Ritesh Kalra Dr. Ritesh Kalra is a highly respected internal medicine specialist with decades of service in both private practice and hospital settings. His career spans extensive clinical work, award-winning research, and mentorship of medical students. Trained across prestigious institutions in Poland, New York, and Georgia, Dr. Ritesh Kalra has earned repeated recognition as a Top Doctor in Internal Medicine from 2020 through 2025. Fluent in Hindi and Punjabi, he connects with a diverse patient population and has devoted his career to improving healthcare delivery and patient outcomes. His inspiration for creating the scholarship stems from his belief in the power of education and the critical role that young, motivated doctors will play in the future of global health. Application Details The Dr. Ritesh Kalra Scholarship for Medical Students is open to all undergraduate students enrolled in accredited U.S. institutions who are on an academic track toward becoming a physician. Applicants must submit a 750–1,000-word original essay responding to the following prompt: "In the rapidly evolving field of medicine, how can future doctors balance technological advancement with the human connection that lies at the heart of patient care? Share your thoughts, supported by personal experiences, observations, or aspirations." Submissions should demonstrate critical thinking, originality, and a strong personal commitment to the medical field. Important Dates Application Deadline: May 15, 2026 Winner Announcement: June 15, 2026 The winning essay will be selected by the scholarship review committee based on insight, clarity, creativity, and the ability to convey a compelling vision for the future of healthcare. The $1,000 award will be sent directly to the recipient to support their educational expenses. How to Apply Applicants should send their essay along with their full name, contact information, school name, and field of study to apply@ The subject line should read: Dr. Ritesh Kalra Scholarship Application. The scholarship reflects Dr. Ritesh Kalra's ongoing mission to support the academic journeys of aspiring doctors and to encourage them to integrate technological expertise with compassionate care. Through this program, he hopes to inspire students to pursue medicine not only as a career but as a lifelong service to humanity. Contact InformationSpokesperson: Dr. Ritesh KalraOrganization: Dr. Ritesh Kalra Scholarship for Medical StudentsWebsite: apply@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
